Search Result

Results for "

VEGFR-2/c-Met inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	c-Met/HGFR (20) VEGFR (21) Antibiotic (1) Apoptosis (6) Bacterial (1) c-Kit (2) EGFR (2) FLT3 (2) Interleukin Related (1) Isotope-Labeled Compounds (1) Pyroptosis (1) Reference Standards (5) TAM Receptor (7)
By Research Areas:	Cancer (22) Cardiovascular Disease (1) Infection (1)

Inhibitors & Agonists

Isotope-Labeled Compounds

Targets Recommended: c-Met/HGFR VEGFR

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-12044

Cabozantinib S-malate Maximum Cited Publications 57 Publications Verification XL184 S-malate; BMS-907351 S-malate	VEGFR Apoptosis	Cancer
Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits *VEGFR2, c-Met, Kit, Axl* and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-12076

BMS 777607 10+ Cited Publications BMS 817378	c-Met/HGFR TAM Receptor	Cancer
BMS 777607 (BMS 817378) is a Met-related inhibitor for *c-Met, Axl, Ron* and Tyro3 with IC₅₀s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively, and 40-fold more selective for Met-related targets than Lck, VEGFR-2, and TrkA/B, with more than 500-fold greater selectivity versus all other receptor and non receptor kinases .

HY-13068

Golvatinib 4 Publications Verification E-7050	c-Met/HGFR VEGFR	Cancer
Golvatinib (E-7050) is a potent dual inhibitor of both *c-Met* and *VEGFR2* kinases with IC₅₀s of 14 and 16 nM, respectively.

HY-107145A

Ningetinib 1 Publications Verification	TAM Receptor VEGFR c-Met/HGFR	Cancer
Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC₅₀s of 6.7, 1.9 and <1.0 nM for *c-Met, VEGFR2* and Axl, respectively.

HY-13016S

Cabozantinib-d6 XL184-d₆; BMS-907351-d₆	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively .

HY-18711A

SCR-1481B1 Metatinib anhydrous; c-Met inhibitor 2	Pyroptosis Interleukin Related c-Met/HGFR VEGFR	Cancer
SCR-1481B1 (Metatinib anhydrous; c-Met inhibitor 2) is an inhibitor of the N-terminal fragment of Gasdermin D (GSDMD), with an IC₅₀ of 1.04 μM and a K_a of 0.42 μM in mice. SCR-1481B1 effectively blocks GSDMD-NT oligomerization and pore formation, inhibits GSDMD-mediated pyroptosis (Pyroptosis), preserves mitochondrial integrity, and reduces proinflammatory cytokine secretion. SCR-1481B1 also inhibits angiogenesis, exerts GSDMD-independent antitumor effects, and enhances the infiltration of antitumor immune cells. SCR-1481B1 is also an inhibitor targeting to *c-MET* and *VEGFR2*, can be used in studies related to melanoma and sepsis .

HY-10991

MGCD-265 analog	c-Met/HGFR VEGFR Apoptosis	Cancer
MGCD-265 analog is a potent and oral active inhibitor of *c-Met* and *VEGFR2* tyrosine kinases, with IC₅₀s of 29 nM and 10 nM, respectively. MGCD-265 analog has significant antitumor activity .

HY-13016S1

Cabozantinib-d4 XL184-d₄; BMS-907351-d₄	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-18711

SCR-1481B1 free base Metatinib free base; c-Met inhibitor 2 free base	c-Met/HGFR VEGFR	Cancer
SCR-1481B1 free base, also known as Metatinib free base, is a small molecule receptor kinase inhibitor that targets both c-MET and vascular endothelial growth factor receptor 2 (VEGFR2) .

HY-147694

c-Met-IN-11	c-Met/HGFR VEGFR	Cancer
c-Met-IN-11 (compound 3) is a potent *c-MET* and *VEGFR-2* inhibitor, with IC₅₀ values of 41.4 and 71.1 nM, respectively .

HY-107145

Ningetinib Tosylate 1 Publications Verification	TAM Receptor VEGFR c-Met/HGFR	Cancer
Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC₅₀s of 6.7, 1.9 and <1.0 nM for *c-Met, VEGFR2* and Axl, respectively.

HY-177134

Taligantinib	VEGFR c-Met/HGFR	Cancer
Taligantinib (Compound Example 70) is an orally active and selective dual inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) and hepatocyte growth factor receptor (c-Met). Taligantinib suppresses tumor angiogenesis and cell proliferation. Taligantinib is promising for research of solid tumors such as non-small cell lung cancer and hepatocellular carcinoma .

HY-10338A

Foretinib phosphate	c-Met/HGFR VEGFR	Cancer
Foretinib phosphate is an orally bioavailable small molecule with potential anti-tumor activity. Foretinib phosphate can selectively inhibit hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), thereby potentially inhibiting tumor angiogenesis, tumor cell proliferation and metastasis. Foretinib phosphate shows different anti-cancer activity from cabozantinib in lung cancer cells and has stronger inhibitory effects on targets such as MEK1/2, FER and AURKB .

HY-120661

T-1840383	c-Met/HGFR VEGFR	Cancer
T-1840383 is a potent, ATP-competitive inhibitor of *c-Met/VEGFR-2, with the IC₅₀s of 1.9 nM, 7.7 nM, 2.2 nM and 5.5 nM for c-Met, VEGFR1, VEGFR2* and VEGFR3, respectively .

HY-13068R

Golvatinib (Standard) E-7050 (Standard)	c-Met/HGFR VEGFR Reference Standards	Cancer
Golvatinib (Standard) is the analytical standard of Golvatinib. This product is intended for research and analytical applications. Golvatinib (E-7050) is a potent dual inhibitor of both c-Met and VEGFR2 kinases with IC50s of 14 and 16 nM, respectively.

HY-149675

VEGFR-2/c-Met-IN-2	VEGFR c-Met/HGFR	Cancer
VEGFR-2/c-Met-IN-2 (compound 3e) is a *VEGFR-2/c-Met* inhibitor, with IC₅₀ values of 83 and 48 nM, respectively. VEGFR-2/c-Met-IN-2 exhibits cytotoxic activity against HCT-116 cell line (IC₅₀: 3.403 µM) .

HY-12044R

Cabozantinib S-malate (Standard) XL184 S-malate (Standard); BMS-907351 S-malate (Standard)	Reference Standards VEGFR Apoptosis	Cancer
Cabozantinib (S-malate) (Standard) is the analytical standard of Cabozantinib (S-malate). This product is intended for research and analytical applications. Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-100833R

Antibiotic-5d (Standard)	Reference Standards Bacterial Antibiotic	Infection
Cabozantinib (S-malate) (Standard) is the analytical standard of Cabozantinib (S-malate). This product is intended for research and analytical applications. Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-W706452

Cabozantinib-d4 S-malate XL184-d4 S-malate; BMS-907351-d4 S-malate	Isotope-Labeled Compounds Apoptosis VEGFR	Cancer
Cabozantinib-d₄ (S-malate) (XL184-d₄ (S-malate); BMS-907351-d₄ (S-malate)) is the deuterium labeled Cabozantinib (S-malate) (HY-12044). Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-181776

c-Met-IN-31	c-Met/HGFR VEGFR EGFR	Cancer
c-Met-IN-31 is a *c-Met* inhibitor with an IC₅₀ value of 0.021 μM. c-Met-IN-31 also inhibits VEGFR-2 and EGFR activities, with IC₅₀ values of 0.32 μM and 9.3 μM, respectively. c-Met-IN-31 inhibits cancer cell proliferation. c-Met-IN-31 suppresses neovascularization in the chick chorioallantoic membrane (CAM) assay, exhibiting in vivo anti-angiogenic activity. c-Met-IN-31 can be used in research related to breast cancer and lung cancer .

HY-147695

c-Met-IN-12	c-Met/HGFR	Cancer
c-Met-IN-12 (compound 4r) is an orally active, potent and selective type II c-Met kinase inhibitor, with an IC₅₀ of 10.6 nM. c-Met-IN-12 displays high inhibitory effects (inhibition rate > 80% in 1 μM) against AXL, Mer and TYRO3 kinases. c-Met-IN-12 can be used a scaffold for further kinase selectivity enhancement. c-Met-IN-12 shows antitumor efficacy .

HY-107145R

Ningetinib Tosylate (Standard)	Reference Standards TAM Receptor VEGFR c-Met/HGFR	Cancer
Ningetinib Tosylate (Standard) is the analytical standard of Ningetinib Tosylate (HY-107145). This product is intended for research and analytical applications. Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine K_inase inhibitor (TK_i) with IC₅₀s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.

HY-107145AR

Ningetinib (Standard)	Reference Standards TAM Receptor VEGFR c-Met/HGFR	Cancer
Ningetinib (Standard) is the analytical standard of Ningetinib (HY-107145A). This product is intended for research and analytical applications. Ningetinib is a potent, orally bioavailable small molecule tyrosine K_inase inhibitor (TK_i) with IC₅₀s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.

HY-181775

VEGFR-2/c-Met/EGFR-IN-1	VEGFR c-Met/HGFR EGFR	Cardiovascular Disease
VEGFR-2/c-Met/EGFR-IN-1 is a *VEGFR-2/c-Met/EGFR* inhibitor with IC₅₀ values of 0.014 μM, 0.072 μM, and 0.94 μM, respectively. c-Met-IN-27 inhibits neovascularization in the chick chorioallantoic membrane (CAM) assay and exhibits in vivo anti-angiogenic activity. c-Met-IN-27 can be used in angiogenesis-related research .

Cat. No.	상품명	Chemical Structure

HY-13016S

Cabozantinib-d6
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively .

HY-13016S1

Cabozantinib-d4
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-W706452

Cabozantinib-d4 S-malate
Cabozantinib-d₄ (S-malate) (XL184-d₄ (S-malate); BMS-907351-d₄ (S-malate)) is the deuterium labeled Cabozantinib (S-malate) (HY-12044). Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

Name
이메일 *

	Sorry, but the email address you supplied was invalid.